Division of Nephrology and Hypertension, IIS-Fundación Jiménez Díaz, Autonoma University, Madrid, Spain.
Clin J Am Soc Nephrol. 2012 Jan;7(1):175-84. doi: 10.2215/CJN.01970211. Epub 2011 Nov 17.
Hematuria is a common finding in various glomerular diseases. This article reviews the clinical data on glomerular hematuria and kidney injury, as well as the pathophysiology of hematuria-associated renal damage. Although glomerular hematuria has been considered a clinical manifestation of glomerular diseases without real consequences on renal function and long-term prognosis, many studies performed have shown a relationship between macroscopic glomerular hematuria and AKI and have suggested that macroscopic hematuria-associated AKI is related to adverse long-term outcomes. Thus, up to 25% of patients with macroscopic hematuria-associated AKI do not recover baseline renal function. Oral anticoagulation has been associated with glomerular macrohematuria-related kidney injury. Several pathophysiologic mechanisms may account for the tubular injury found on renal biopsy specimens. Mechanical obstruction by red blood cell casts was thought to play a role. More recent evidence points to cytotoxic effects of oxidative stress induced by hemoglobin, heme, or iron released from red blood cells. These mechanisms of injury may be shared with hemoglobinuria or myoglobinuria-induced AKI. Heme oxygenase catalyzes the conversion of heme to biliverdin and is protective in animal models of heme toxicity. CD163, the recently identified scavenger receptor for extracellular hemoglobin, promotes the activation of anti-inflammatory pathways, opening the gates for novel therapeutic approaches.
血尿是各种肾小球疾病的常见表现。本文回顾了肾小球性血尿和肾损伤的临床数据,以及血尿相关肾损伤的病理生理学。尽管肾小球性血尿被认为是肾小球疾病的一种临床表现,对肾功能和长期预后没有实际影响,但许多研究表明,大量肾小球性血尿与急性肾损伤(AKI)之间存在关联,并提示与大量血尿相关的 AKI 与不良的长期结局相关。因此,多达 25%的大量血尿相关 AKI 患者无法恢复到基线肾功能。口服抗凝剂与肾小球性大量血尿相关的肾损伤有关。几种病理生理机制可能解释了肾活检标本中发现的肾小管损伤。红细胞管型的机械阻塞被认为起作用。最近的证据表明,由血红蛋白、血红素或红细胞释放的铁引起的氧化应激的细胞毒性作用。这些损伤机制可能与血红蛋白尿或肌红蛋白尿引起的 AKI 共享。血红素加氧酶催化血红素转化为胆红素,并在血红素毒性的动物模型中具有保护作用。CD163 是最近鉴定的细胞外血红蛋白的清道夫受体,可促进抗炎途径的激活,为新的治疗方法开辟了道路。